NASDAQ · IRWD
Ironwood Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IRWD: Nov 9, 2026
Ironwood Pharmaceuticals, Inc. Class A Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $0.3. The reported EPS for the same quarter last year was $0.24.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.30 | $0.30 | $0.30 | 1 |
| Dec 2026 | $0.25 | $0.25 | $0.25 | 1 |
| Mar 2027 | $0.03 | $0.03 | $0.03 | 1 |
| Jun 2027 | $0.03 | $0.03 | $0.03 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · The Motley Fool · MarketBeat- RTTNews · Oct 16, 7:58 AM EDTIronwood Pharmaceuticals Promotes COO Tammi Gaskins To Succeed Tom McCourt As CEO(RTTNews) – Biotechnology company Ironwood Pharmaceuticals, Inc. (IRWD) announced Friday that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027.
- Zacks · Oct 7, 9:57 AM EDTWill Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
- Zacks · Sep 30, 11:08 AM EDTPGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
- Zacks · Sep 21, 9:50 AM EDTIronwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Zacks · Sep 14, 9:30 AM EDT5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryINDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
- The Motley Fool · Aug 13, 1:43 PM EDTIronwood (IRWD) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 7, 12:53 PM EDTIronwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View RaisedIRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.
- MarketBeat · Aug 6, 4:04 PM EDTIronwood Pharmaceuticals Q2 Earnings Call Highlights3 Stocks Trading Near $5 With Massive Earnings UpsideIronwood Pharmaceuticals (NASDAQ:IRWD) reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its convertible notes, promptin
- Zacks · Aug 6, 9:50 AM EDTIronwood Pharmaceuticals (IRWD) Q2 Earnings Top EstimatesIronwood (IRWD) delivered earnings and revenue surprises of +19.23% and -5.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 6, 7:34 AM EDTIronwood Pharmaceuticals, Inc. Profit Advances In Q2(RTTNews) – Ironwood Pharmaceuticals, Inc. (IRWD) revealed earnings for its second quarter that Increases, from last year
- Zacks · Jul 23, 11:36 AM EDTCommunity Health Q2 Loss Wider Than Expected, 2026 View LoweredCYH posts a wider-than-expected Q2 loss as revenues fall and the company cuts its 2026 revenue, EBITDA and earnings outlook.
- Zacks · Jul 16, 12:15 PM EDTUnitedHealth Tops Q2 Earnings on Cost Control, Raises '26 OutlookUNH beats Q2 earnings estimates on lower medical costs and stronger Optum Insight, then raises its 2026 EPS and cash flow outlook.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Ironwood Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.